Related Experiment Videos
Feasibility of Compressed Chemotherapy Pediatric Ewing Sarcoma Regimen In Pakistan
Haleema Saeed1, Rishm Ali1, Saadiya Javed Khan1
1Department of Paediatric Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.
Insights
A compressed chemotherapy regimen is feasible for pediatric Ewing sarcoma (ES) patients, with most completing treatment on time. This approach shows promise for improving outcomes in young ES patients.
Area of Science:
- Pediatric Oncology
- Medical Feasibility Studies
Background:
- Ewing sarcoma (ES) is a rare bone cancer primarily affecting children and young adults.
- Standard chemotherapy regimens can be lengthy, posing challenges for pediatric patients.
- Optimizing treatment delivery is crucial for improving patient outcomes.
Purpose of the Study:
- To assess the feasibility of an interval-compressed chemotherapy regimen in pediatric patients with Ewing sarcoma.
- To evaluate treatment completion rates, duration, and associated complications.
Main Methods:
- Retrospective chart review of 24 pediatric Ewing sarcoma patients treated between June 2017 and December 2018.
- Data collected included demographics, treatment timing, complications, and outcomes.
- Treatment completion within 8 months was defined as 'on time'.
Main Results:
- 83.3% of patients completed chemotherapy within the planned 8-month timeframe.
- The mean treatment duration was 7.2 ±1.2 months.
- 17 (70.8%) patients were alive at the time of review, with complications including febrile neutropenia, sepsis, cardiac failure, and progressive disease.
Conclusions:
- An interval-compressed chemotherapy regimen is feasible and tolerable for pediatric Ewing sarcoma patients.
- Adequate supportive care is essential for managing complications associated with this intensified treatment protocol.
- This approach may offer a more efficient treatment strategy for pediatric ES.
Abstract:
A retrospective chart review was conducted to determine the feasibility of interval-compressed chemotherapy regimen in pediatric Ewing sarcoma (ES) patients treated at Department of Pediatric Oncology, Shaukat Khanum Memorial Trust Cancer Hospital, Lahore, Pakistan, from June 2017 to December 2018. Data was collected regarding demographics, treatment duration and timing, complications and outcome. Completion of treatment within 8 months as considered on time. There were 24 patients (male: female ratio = 1.4:1, average age = 10.2 ±5.3 years. Involved sites were extremity in 13 (54%), pelvis in 4 (16.6%), and spine in 3 (12.5%) patients. Twenty patients (83.3%) completed chemotherapy on time. The mean duration of treatment was 7.2 ±1.2 months. Only three patients (12%) exceeded 8 months of duration of treatment. There was an average of 2.5 febrile neutropenia events per patient. Seventeen (70.8%) patients are alive at the time of review. Two patients died of sepsis, one developed cardiac failure, and one died of progressive disease. This single-institution review showed that patients can tolerate interval-compressed chemotherapy protocol regimen for ES with adequate supportive care. Key Words: Ewing sarcoma, chemotherapy, Compressed regimen, feasibility, Pediatrics.